Prevention programs: ideas, complications and illustrations. In Confronting AIDS. Edited by Turner CF, Miller HG, Moses LE. Washington DC: National Academy Press; 1989:47199. 24. Foss AM, Vickerman PT, Mayaud P, Weiss H, Ramesh BM, Reza-Paul S, Washington R, Blanchard J, Moses S, Lowndes CM, et al: Modelling the interactions among HSV-2 and HIV: implications for the HIV epidemic in southern India. Sex Transm Infect 2011, 87:227. 25. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O, Kiwanuka N, Kigozi G, Kiddugavu M, Lutalo T, et al: Prices of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005, 191:1403409. 26. Shisana O, Simbayi L: Nelson Mandela/HSRC study of HIV/AIDS. South African National HIV Prevalence, Behavioural Risks and Mass Media. The Human Sciences Study Council: Cape Town; 2002. 27. Johnson LF, Coetzee DJ, Dorrington RE: Sentinel surveillance of sexually transmitted infections in South Africa: a critique. Sex Transm Infect 2005, 81:28793. 28. Picking out Interventions which can be Cost Successful (WHO-CHOICE). [http://www.who.int/choice/costs/CER_thresholds/en/] 29. Bassett IV, Giddy J, Nkera J, Wang B, Losina E, Lu Z, Freedberg KA, Walensky RP: Routine voluntary HIV testing in Durban, South Africa: the encounter from an outpatient division. J Acquir Immune Defic Syndr 2007, 46:18186. 30. Terris-Prestholt F, Kumaranayake L, Obasi AI, Cleophas-Mazige B, Makokha M, Todd J, Ross DA, Hayes RJ: From Trial Intervention to Scale-Up: Fees of An Adolescent Sexual Overall health Plan in Mwanza, Tanzania. Sex Transm Dis 2006, 33:S13339. 31. Terris-Prestholt F, Michaels C, Kumaranayake L, Meyer-Rath G, Watts C: Costing Microbicide Distribution: Estimating cost-effectiveness modelling potential part out. Entebbe, Uganda: MDP301 Annual Investigators Meeting; 2009. 32. Meyer-Rath G: Public Sector Salary Costs. ; 2009. Personal Communicatuion. 33. Cleary S, Bouille A, McIntyre D, et al: Cost-effectiveness of Antiretroviral Remedy for HIV-positive Adults within a South African Township. Cape Town: University of Cape Town, Health Systems Trust, Medecins Sans Frontieres; 2004. 34. Gilson L, Mkanje R, Grosskurth H, Mosha F, Picard J, Gavyole A, Todd J, Mayaud P, Swai R, Fransen L, et al: Cost-effectiveness of enhanced treatment solutions for sexually transmitted ailments in stopping HIV-1 infection in Mwanza Region, Tanzania. Lancet 1997, 350:1805809. 35. Bollinger L, Stover J, Boulle A, Cleary S: Database of Unit Charges for HIV and AIDS interventions in South Africa: Resource Demands for HIV/AIDS: Model for estimating sources required for prevention, care and mitigation.Naringenin MedChemExpress In Book Database of Unit Fees for HIV and AIDS interventions in South Africa: Resource Requirements for HIV/AIDS: Model for estimating resources required for prevention, care and mitigation.NPPB medchemexpress City: Centre for Financial Governance and AIDS in Africa; 2006.PMID:24025603 36. Buddy D: Tenofovir 1 gel, Current Rates and Expected Rates at Unique Scales. 2012. Private communication. 37. Johnson L: Access to antiretroviral remedy in South Africa, 2004011. S Afr J HIV Med 2012, march:227. 38. Meyer-Rath G: National ART Expense Model, South Africa. Johannesburg: Overall health Economics and Epidemiology Investigation Office, Boston University/University on the Witwatersrand; 2011. 39. Johansson KA, Robberstad B, Norheim OF: Additional Added benefits by Early Get started of HIV Therapy in Low Revenue Countries: Survival Estimates of Early Versus Deferred Antiretrovi.
